Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman

Chemico-Biological Interactions

Volumn 157-158, Issue , 2005, Pages 239-246

  Gordon, Richard K ^a   Haigh, Julian R ^a   Garcia, Gregory E ^a   Feaster, Shawn R ^a   Riel, Michael A ^b   Lenz, David E ^c   Aisen, Paul S ^d   Doctor, Bhupendra P ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acetylcholinesterase; Butyrylcholinesterase; High throughput screening; Huperzine A; Pyridostigmine bromide; Robotics; Soman

Indexed keywords

ACETYLCHOLINESTERASE; CHEMICAL WARFARE AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HUPERZINE A; ORGANOPHOSPHATE; PYRIDOSTIGMINE; SOMAN;

ALZHEIMER DISEASE; BLOOD SAMPLING; CHOLINESTERASE BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTOXICATION; MEMORY; NEUROPROTECTION; PROPHYLAXIS; SOLDIER; TERRORISM; WAR; WASTE MANAGEMENT;

ADMINISTRATION, ORAL; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; ERYTHROCYTES; HUMANS; NEUROPROTECTIVE AGENTS; PYRIDOSTIGMINE BROMIDE; SESQUITERPENES; SOMAN;

EID: 28644452680     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2005.10.031     Document Type: Conference Paper

References (18)

1. A. Silver The Biology of Cholinesterases 1974 North Holland Publishing Company Amsterdam pp. 58-67
2. O. Lockridge, and P. Masson Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk Neurotoxicology 21 1-2 2000 113 126
3. P. Taylor, in: A.G., Gilman, T.W., Rall, A.S., Neis, P., Taylor (Eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, eighth ed., 1990, pp. 131-149.
4. V.E.V. St. Omer, and G.E. Rottinghaus Biochemical determination of cholinesterase activity in biological fluids and tissues B. Ballantyne T.C. Marrs Clinical and Experimental Toxicology of Organophosphates and Carbamates 1992 Butterworth & Heinemann Oxford 15 27
5. M.W. Jann, K.L. Shirley, and G.W. Small Clinical Pharmacokinetics and pharmacodynamics of cholinesterase inhibitors Clin. Pharmacokinet. 41 10 2002 719 739
6. M.S. Juhn Myasthenia gravis. Diagnostic methods and control measures for a chronic disease Postgrad Med. 94 5 1993 161 171
7. L. Ember, Probe of troop's exposure to chemical arms failed, Chem. Eng. News, 1996, pp. 40-41.
8. J.W. Gardner, R.V. Gibbons, T.I. Hooper, S.O. Cunnion, K. Kroeenke, and G.D. Gackstetter Identifying new diseases and their causes: the dilemma of illnesses in Gulf War veterans Mil. Med. 168 3 2003 186 193
9. M.B. Abou-Donia, K.R. Wilmarth, K.F. Jensen, F.W. Oehme, and T.L. Kurt Neurotoxicity resulting from coexposure to pyridostigmine bromide, deet, and permethrin: implications of Gulf War chemical exposures J. Toxicol. Environ. Health 48 1 1996 35 56
10. S. Feaster, R. Gordon, B. Doctor, Assay for detecting, measuring and monitoring the activities and concentrations of proteins and methods of use thereof. US patent # 6,746,850, Issued June 8, 2004.
11. S.R. Feaster, R.K. Gordon, C.C. Clark, D.M. Maxwell, D.E. Lenz, B.P. Doctor, Unprocessed Whole Blood Cholinesterase Levels: WRAIR Protocol Development and Validation. USAMRMC Bioscience Review, 2000, Hunt Valley, MD.
12. J.R. Haigh, G.E. Garcia, D.R. Moorad-Doctor, M.S. Farah, R. Brueckner, S.R. Feaster, B.P. Doctor, R.K. Gordon, D.E. Lenz, C.R. Clark, M.R. Riel, P.S. Aisen, W. Smart, J. Mo, B.J. Sullivan, Jr.-H. Tsai, The WRAIR Whole Blood Cholinesterase Assay - Current Pyridostigmine Bromide and Huperzine A Studies and Future Cholinesterase Screening. USAMRMC Bioscience Review, 2004, Hunt Valley, MD.
13. H. Jiang, X. Luo, and D. Bai Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional medicine origin for the treatment of Alzheimer's disease Curr. Med. Chem. 10 21 2003 2231 2252
14. E. Bieberich, and R.K. Yu Multi-enzyme kinetic analysis of glycolipid biosynthesis Biochim. Biophys. Acta 1432 1 1999 113 124
15. G.E. Garcia, D. Moorad-Doctor, Novel and sensitive pyridostigmine bromide HPLC assay. USAMRMC Bioscience Review, 2004, Hunt Valley, MD.
16. http://www.fda.gov/cder/drug/infopage/Pyridostigmine_Bromide/default.htm.
17. R.K. Gordon, S.V. Nigam, J.A. Weitz, J.R. Dave, B.P. Doctor, and H.S. Ved The NMDA receptor ion channel: a site for binding of Huperzine A J Appl. Toxicol. Suppl. 1 2001 S47 S51
18. G. Lallement, V. Baille, D. Baubichon, P. Carpentier, J.M. Collombet, P. Filliat, A. Foquin, E. Four, C. Masqueliez, G. Testylier, L. Tonduli, and F. Dorandeu Review of the value of huperzine as pretreatment of organophosphate poisoning Neurotoxicology 23 2002 1 5